Neovacs Balance Sheet Health
Financial Health criteria checks 1/6
Neovacs has a total shareholder equity of €18.6M and total debt of €480.6K, which brings its debt-to-equity ratio to 2.6%. Its total assets and total liabilities are €43.9M and €25.3M respectively.
Key information
2.6%
Debt to equity ratio
€480.62k
Debt
| Interest coverage ratio | n/a |
| Cash | €231.61k |
| Equity | €18.63m |
| Total liabilities | €25.29m |
| Total assets | €43.92m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ALNEV's short term assets (€2.8M) do not cover its short term liabilities (€4.2M).
Long Term Liabilities: ALNEV's short term assets (€2.8M) do not cover its long term liabilities (€21.0M).
Debt to Equity History and Analysis
Debt Level: ALNEV's net debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: ALNEV's debt to equity ratio has increased from 1.3% to 2.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNEV has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALNEV has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.4% each year.